GlassScriptPhysician profile
Frankie C Cate
NPI 1619479789
$4,228.76
in general payments reported to CMS, 2019-2025
27 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 87% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $592 · 2023: $1,291 · 2024: $1,326 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,636.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $682.23 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $673.53 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $412.35 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $261.32 | 2023-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $228.05 | 2023-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $220.16 | 2024 | Arcalyst |
| Pfizer INC. | $199.45 | 2022-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $195.76 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $156.52 | 2025 | |
| Boston Scientific Corporation | $153.11 | 2023-2025 | Watchman Flx, Bodyguardian |
| Bayer Healthcare Pharmaceuticals INC. | $136.60 | 2023-2025 | |
| Medtronic, INC. | $136.35 | 2024-2025 | Symplicity G3 |
| Inspire Medical Systems, INC. | $115.36 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.44 | 2022-2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $78.37 | 2024-2025 | Uptravi, Opsumit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $59.83 | 2023-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $57.92 | 2024 | |
| Abiomed | $55.91 | 2023 | Impella |
| Astrazeneca Pharmaceuticals LP | $53.29 | 2022-2024 | Farxiga |
| Daiichi Sankyo INC. | $52.83 | 2023 | Injectafer |
| Philips North America LLC | $44.48 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Scpharmaceuticals INC. | $43.13 | 2025 | |
| Alnylam Pharmaceuticals INC. | $37.46 | 2022-2023 | Amvuttra |
| Cvrx, INC. | $27.93 | 2024 | Barostim Neo System |
| Baxter Healthcare | $21.47 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Heartflow, INC. | $19.52 | 2024 | |
| Amarin Pharma, INC. | $19.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frankie Cate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.